MorphoSys AG (MOR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.28+0.05 (+0.18%)
As of 10:48AM EST. Market open.
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 28.23 |
| Open | 28.12 |
| Bid | 28.31 x 900 |
| Ask | 28.36 x 800 |
| Day's Range | 28.09 - 28.32 |
| 52 Week Range | 18.21 - 37.96 |
| Volume | 13,817 |
| Avg. Volume | 65,322 |
| Market Cap | 3.676B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- Insider Monkey
Where Do Hedge Funds Stand On MorphoSys AG (MOR)?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Motley Fool
MorphoSys AG (MOR) Q3 2020 Earnings Call Transcript
MOR earnings call for the period ending September 30, 2020.
- Zacks
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.
© 2020 Verizon Media. All rights reserved.
